BIONET-EUROPE
BioNet Europe, the French subsidiary of BioNet, a vaccine manufacturer specializing in the development of genetically engineered vaccines, has announced the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its monovalent Recombinant Pertussis Vaccine (RPV).
BioNet’s stand-alone vaccine targets whooping cough, a highly contagious respiratory disease on the steep rise across Europe. This non-combined vaccine is tailored to the persons who require pertussis-only booster vaccination and are up-to-date with their diphtheria and tetanus immunizations.
Dr Giuseppe Del Giudice, Director Translational Research at BioNet, stated, “BioNet’s recombinant vaccine is designed to provide more effective and longer-lasting immune protection against pertussis than traditional acellular pertussis vaccines. It contains a Pertussis Toxin (PT), the main component responsible for severe pertussis disease, which is inactivated by recombinant technologies rather than chemicals.”
These recombinant technologies allow for the preservation of the native structure of the PT, fundamental for the induction of higher immune protection. Currently, no other monovalent or recombinant pertussis vaccines are available in Europe, making BioNet’s RPV a best-in-class vaccine driving significant advancement in public health with the potential to improve acceptance for pertussis immunization.
Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease. After receiving the positive feedback from EMA Scientific Advice, we are honored to have our MAA submission validated by the EMA as well.”
The safety, immunogenicity and antibody persistence induced after one single booster dose of BioNet’s RPV were demonstrated in numerous randomized clinical trials, notably amongst adults in Australia, adolescents in Switzerland, as well as vulnerable populations such as pregnant women and elderly in Thailand.
The vaccine is licensed in Asia (under the Pertagen® trademark) and is included in the pertussis maternal immunization program for pregnant women in Thailand. The MAA of Pertagen® has also been submitted to the Australian Therapeutic Goods Administration.
About BioNet
BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced over three proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across Asia, Europe and North America.
Forward-Looking Statements
This press release contains forward-looking statements relating to BioNet’s business, including regulatory submissions. These statements are based on current expectations as of the date of this press release and involve known and unknown risks and uncertainties that may cause actual results to differ materially. BioNet disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730521754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Launches UAE CFD Shares on MultiBank-Plus App and MT5 Platform11.2.2025 13:17:00 CET | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, announces the launch of UAE Contracts for Difference (CFD) shares on its innovative MultiBank-Plus App and MT5 platform. This expansion enables investors to trade Dubai Financial Market (DFM) and Abu Dhabi Securities Exchange (ADX) shares across all account types, including Standard, Pro, and ECN. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211323821/en/ MultiBank Group Launches UAE CFD Shares on MultiBank-Plus and MT5 Platform Expanding Trading Opportunities for Investors (Graphic: Business Wire) This launch reinforces the firm’s commitment to innovation and expanding market access for account holders worldwide. By introducing UAE CFD shares on MultiBank-Plus App & MT5, the Group empowers traders to diversify their portfolios and leverage opportunities in the UAE’s growing investment landscape. With this development, MultiBank Group now al
Nanoco Refocuses on Strategic Growth11.2.2025 13:00:00 CET | Press release
Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, has completed several organisational changes designed to accelerate its commercial development. In October 2024, Dmitry Shashkov joined as Chief Executive Officer. He has a proven 20 year plus track record in leading materials science-based businesses, driving shareholder value through transformational business development. Dmitry was CEO of the CPS Group of companies (later part of Exyte), which focused on high-tech equipment for semiconductors and life science industries. Under his leadership, CPS revenues tripled, and profitability increased fourfold before its sale to a strategic investor. Prior to CPS, Dmitry was President and CEO of H.C. Starck Inc. (a world-leading supplier of refractory metals) and Business Director at Honeywell (a leading supplier of electronic materials). He began his career with McKinsey & Company, advising clients in
Accelera to Power 100 MW Electrolyzer System for bp’s Lingen Green Hydrogen Project11.2.2025 13:00:00 CET | Press release
Accelera™ by Cummins, the zero-emissions business segment of Cummins Inc. [NYSE: CMI], will supply a 100-megawatt (MW) proton exchange membrane (PEM) electrolyzer system for bp's Lingen green hydrogen project in Germany. This project, bp's largest hydrogen production plant to date, will utilize Accelera's advanced HyLYZER® PEM electrolyzer technology. The hydrogen-generation system set to power bp’s Lingen project will consist of 20 PEM HyLYZER®-1000 electrolyzer units — the largest electrolyzer system assembled by Accelera to date — and is being manufactured in Accelera’s new electrolyzer plant in Guadalajara, Spain. Once fully commissioned in 2027, the 100 MW electrolyzer system will produce up to 11,000 tons of green hydrogen per year. "This project marks a significant milestone for Accelera and the energy transition in Germany and Europe," said Andreas Lippert, Vice President and General Manager of Electrolyzers for Accelera. “Partnering on this 100 MW system with an industry leade
comforte AG Warns of Impending March 2025 PCI DSS 4.0 Compliance Deadline11.2.2025 10:41:00 CET | Press release
comforte AG, a global leader in data security, today urged global businesses to finalize their PCI DSS 4.0 plans, ahead of the compliance deadline which falls on 31 March 2025. PCI DSS 4.0 is a major new iteration of the Payment Card Industry Data Security Standard, which applies to any organization which stores, processes or transmits cardholder data. As such, it has an outsized impact on sectors such as financial services and retail. The latest version features over 50 new technical requirements including new rules around data protection mechanisms. A key focus for PCI DSS 4.0 is to encourage cybersecurity as a long-term, continuous process, which is why additional flexibility has been baked into the standard—allowing organizations to choose the security controls most suited to their business. comforte’s tokenization technology is a proven, format-preserving way to safeguard cardholder data in line with PCI DSS 4.0, while preserving data utility. Because sensitive data elements like
Xsolla and AppsFlyer Unveil Custom Integration to Boost Mobile Game Web Shop Performance11.2.2025 10:00:00 CET | Press release
Industry First Collaboration Introduces Cross-Platform Analytics as an Integrated Solution to Solve Mobile and Web Measurement Challenges for Game Developers Xsolla, a leading global video game commerce company, has partnered with AppsFlyer, the global leader in mobile measurement, attribution, and data analytics, in a first-in-the-gaming industry web shop collaboration. This enhancement of the Xsolla and AppsFlyer partnership provides game developers with improved insights and simplified activation for its Web Shop solution, which is available worldwide. It also introduces solutions to address cross-platform measurement and attribution challenges. The partnership includes two integration options: server-to-server (S2S) and web integrations for mobile games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211661118/en/ (Graphic: Xsolla) Xsolla and AppsFlyer have collaborated closely for over a year to develop two custom in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom